

Edgar Filing: MARINE PRODUCTS CORP - Form 8-K

MARINE PRODUCTS CORP
Form 8-K
February 17, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 17, 2004

Commission File No. 1-16263

MARINE PRODUCTS CORPORATION
(exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

58-2572419
(I.R.S. Employer
Identification Number)

2170 Piedmont Road, NE, Atlanta, Georgia
(Address of principal executive offices)

30324
(zip code)

(404) 321-7910
Registrant's telephone number, including area code

Item 12. Results of Operations and Financial Condition

On February 17, 2004, registrant issued a press release titled, "Marine Products Corporation Reports Record 2003 Fourth Quarter and Full Year Results " that announced the results of the fourth quarter ended December 31, 2003 and the fiscal year ended December 31, 2003.

Item 7. Financial Statements and Exhibits

(c) Exhibits.

Exhibit 99 - Press release dated February 17, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Marine Products Corporation.

Date: February 17, 2004

/s/ BEN M. PALMER

Ben M. Palmer
Vice President,
Chief Financial Officer
and Treasurer

ter" style="margin:0in 0in .0001pt;text-align:center;">**EPIX Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware

Edgar Filing: MARINE PRODUCTS CORP - Form 8-K

(State or Other Jurisdiction of Incorporation)

000-21863

(Commission File Number)

04-3030815

(IRS Employer Identification No.)

161 First Street, Cambridge, Massachusetts

02142

Edgar Filing: MARINE PRODUCTS CORP - Form 8-K

(Address of Principal Executive Offices)

(Zip Code)

(617) 250-6000

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On February 17, 2005, EPIX Pharmaceuticals, Inc. issued a press release that announced its financial results for the fourth quarter ended December 31, 2004 and for full year 2004. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed to be filed for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the Exchange Act) and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(c) The following exhibits are furnished with this report:

Exhibit Number	Description
99.1	Press Release dated February 17, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Pharmaceuticals, Inc.
(Registrant)

Date: February 17, 2005

/s/ Peyton J. Marshall
Peyton J. Marshall
*Senior Vice-President,
Finance and Administration,
Chief Financial Officer*